Tissium SA (Tissium), fomerly known as Gecko Biomedical, is a life science company that provides polymer solutions for tissue reconstruction. The company offers a platform that validates the technology in surgical spaces, including peripheral nerve reconstruction, ophthalmology, urology, and orthopaedics. It offers medical devices such as surgical glues and patches for wound closures. Gecko’s proprietary technology platform is composed of fully synthetic light-activated materials that can be printed inside the body acting as sealants, adhesives, barriers or plugs or outside the body through 3D printing to provide high resolution implantable devices. The company operates through laboratory and factory office located in France. Tissium is headquartered in Paris, Île-de-France, France.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Tissium SA
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Tissium SA Company Overview
- Tissium SA Company Snapshot
- Tissium SA Pipeline Products and Ongoing Clinical Trials Overview
- Tissium SA - Pipeline Analysis Overview
- Tissium SA - Key Facts
- Tissium SA - Major Products and Services
- Tissium SA Pipeline Products by Development Stage
- Tissium SA Ongoing Clinical Trials by Trial Status
- Tissium SA Pipeline Products Overview
- Drug-Eluting Adhesive - Chronic Rhinosinusitis
- Drug-Eluting Adhesive - Chronic Rhinosinusitis Product Overview
- GB-02 - Tissue Reconstruction
- GB-02 - Tissue Reconstruction Product Overview
- GB-04 - Sutureless Closure
- GB-04 - Sutureless Closure Product Overview
- Hernia Repair Adhesive
- Hernia Repair Adhesive Product Overview
- Hernia Repair Adhesive Clinical Trial
- SETALUM Sealant
- SETALUM Sealant Product Overview
- Sutureless Nerve Coaptation Device
- Sutureless Nerve Coaptation Device Product Overview
- Sutureless Nerve Coaptation Device Clinical Trial
- Tissium SA - Key Competitors
- Tissium SA - Key Employees
- Tissium SA - Locations And Subsidiaries
- Head Office
- Recent Developments
- Tissium SA, Recent Developments
- Sep 12, 2023: First Patients Treated with Tissium’s Atraumatic Hernia Repair System
- Mar 30, 2023: First patients treated with TISSIUM’s at raumatic sutureless nerve coaptation system
- Jan 17, 2023: TISSIUM appoints Alex Milstein as Chief Medical Officer
- Sep 26, 2022: TISSIUM appoints Sara Toyloy as Independent Board Member
- Jul 12, 2022: Tissium Appoints Maria Sainz as Independent Board Member
- Feb 02, 2022: 5 Sofinnova Partners Portfolio Companies Selected to French Tech 120
- Oct 06, 2021: TISSIUM to present study results at the Hernia 2021 European Hernia Society - American Hernia Society Joint Congress
- Sep 24, 2021: TISSIUM to Present Study Results at the 76th Annual Meeting of the American Society for Surgery of the Hand
- Feb 03, 2021: TISSIUM Adds to Executive Leadership Team
- Nov 17, 2020: TISSIUM receives FDA investigational device exemption for vascular sealant
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Tissium SA Pipeline Products and Ongoing Clinical Trials Overview
- Tissium SA Pipeline Products by Equipment Type
- Tissium SA Pipeline Products by Indication
- Tissium SA Ongoing Clinical Trials by Trial Status
- Tissium SA, Key Facts
- Tissium SA, Major Products and Services
- Tissium SA Number of Pipeline Products by Development Stage
- Tissium SA Pipeline Products Summary by Development Stage
- Tissium SA Ongoing Clinical Trials by Trial Status
- Tissium SA Ongoing Clinical Trials Summary
- Drug-Eluting Adhesive - Chronic Rhinosinusitis - Product Status
- Drug-Eluting Adhesive - Chronic Rhinosinusitis - Product Description
- GB-02 - Tissue Reconstruction - Product Status
- GB-02 - Tissue Reconstruction - Product Description
- GB-04 - Sutureless Closure - Product Status
- GB-04 - Sutureless Closure - Product Description
- Hernia Repair Adhesive - Product Status
- Hernia Repair Adhesive - Product Description
- Hernia Repair Adhesive - ALPHA: A Pilot Study to Evaluate the Initial Safety and Performance of the TISSIUM Adhesive Hernia Repair System (TAHRS) for Atraumatic Laparoscopic Hernia Repair
- SETALUM Sealant - Product Status
- SETALUM Sealant - Product Description
- Sutureless Nerve Coaptation Device - Product Status
- Sutureless Nerve Coaptation Device - Product Description
- Sutureless Nerve Coaptation Device - A Clinical Investigation of Tissium's Coaptium Connect Atraumatic Sutureless Nerve Coaptation System
- Sutureless Nerve Coaptation Device - A Prospective, Multicenter, Single-arm Clinical Trial Evaluating Safety and Performance of TISSIUM Nerve Coaptation Device for the Repair of Digital Nerve Discontinuities where Gap Closure Can be Achieved by Flexion of the Extremity
- Tissium SA, Key Employees
- Glossary
- Tissium SA Pipeline Products by Equipment Type
- Tissium SA Pipeline Products by Development Stage
- Tissium SA Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pixium Vision SA
- Varioptic SA
- Imagine Eyes SA
- Varioptic SA
- Pixium Vision SA
- Imagine Eyes SA
